TA-MUC1, the target of gatipotuzumab ... Since 2023, ADCs have dominated high-value pharmaceutical deals. The global ADC market is expected to grow as currently approved and pipeline ADCs become ...

"MUC1 is over-expressed in multiple solid tumors including colon, pancreatic, ovarian, breast, and NSCLC, and is associated with drug resistance and poor patient outcomes. This results in an unmet ...